Tourmaline Bio to Present at Upcoming Investor Conferences
Tourmaline Bio (NASDAQ: TRML) has announced its participation in two upcoming investor conferences. Dr. Sandeep Kulkarni, Co-Founder and CEO, will participate in the Truist Securities BioPharma Symposium in New York on November 7, 2024, speaking on a panel about cardiac and skeletal muscle illnesses at 2:35 pm ET. He will also join a fireside chat at the Guggenheim Securities Healthcare Innovation Conference in Boston on November 12, 2024, at 1:30 pm ET.
Live webcasts and replays will be accessible through the company's investor relations website at ir.tourmalinebio.com under 'Events and Presentations.'
Tourmaline Bio (NASDAQ: TRML) ha annunciato la sua partecipazione a due conferenze per investitori in arrivo. Dr. Sandeep Kulkarni, co-fondatore e CEO, parteciperà al Truist Securities BioPharma Symposium a New York il 7 novembre 2024, intervenendo in un panel sulle malattie cardiache e muscolari scheletriche alle 14:35 ET. Parteciperà anche a una chiacchierata informale alla Guggenheim Securities Healthcare Innovation Conference a Boston il 12 novembre 2024, alle 13:30 ET.
Le dirette web e le registrazioni saranno accessibili tramite il sito web delle relazioni con gli investitori dell'azienda all'indirizzo ir.tourmalinebio.com nella sezione 'Eventi e Presentazioni.'
Tourmaline Bio (NASDAQ: TRML) ha anunciado su participación en dos conferencias para inversores que se avecinan. Dr. Sandeep Kulkarni, cofundador y CEO, participará en el Truist Securities BioPharma Symposium en Nueva York el 7 de noviembre de 2024, hablando en un panel sobre enfermedades musculares cardíacas y esqueléticas a las 2:35 pm ET. También se unirá a una charla informal en la Conferencia de Innovación en Salud de Guggenheim Securities en Boston el 12 de noviembre de 2024, a la 1:30 pm ET.
Las transmisiones en vivo y las grabaciones estarán disponibles a través del sitio web de relaciones con inversores de la compañía en ir.tourmalinebio.com bajo 'Eventos y Presentaciones.'
투어말린 바이오 (NASDAQ: TRML)는 다가오는 두 개의 투자자 회의에 참가한다고 발표했습니다. 산디프 쿨카르니 박사, 공동 설립자 겸 CEO가 2024년 11월 7일 뉴욕에서 열리는 트루이스트 증권 생명?의학 심포지엄에 참여하여 오후 2시 35분 ET에 심장 및 골격근 질환에 관한 패널에 참가할 예정입니다. 또한 2024년 11월 12일 보스턴에서 열리는 구겐하임 증권 헬스케어 혁신 회의에서 오후 1시 30분 ET에 파이어사이드 채팅에 참여할 예정입니다.
실시간 웹캐스트와 재방송은 회사의 투자자 관계 웹사이트인 ir.tourmalinebio.com의 '이벤트 및 프레젠테이션' 섹션을 통해 제공됩니다.
Tourmaline Bio (NASDAQ: TRML) a annoncé sa participation à deux conférences pour investisseurs à venir. Dr. Sandeep Kulkarni, co-fondateur et PDG, participera au Truist Securities BioPharma Symposium à New York le 7 novembre 2024, où il interviendra lors d'un panel sur les maladies musculaires cardiaques et squelettiques à 14h35 ET. Il prendra également part à une conversation informelle lors de la Conférence sur l'Innovation en Santé de Guggenheim Securities à Boston le 12 novembre 2024, à 13h30 ET.
Les webcasts en direct et les rediffusions seront accessibles via le site de relations investisseurs de l'entreprise à l'adresse ir.tourmalinebio.com dans la section 'Événements et Présentations.'
Tourmaline Bio (NASDAQ: TRML) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Dr. Sandeep Kulkarni, Mitgründer und CEO, wird am 7. November 2024 am Truist Securities BioPharma Symposium in New York teilnehmen und um 14:35 Uhr ET an einem Panel über Herz- und Skelettmuskelerkrankungen sprechen. Er wird auch an einem Fireside-Chat auf der Guggenheim Securities Healthcare Innovation Conference in Boston am 12. November 2024 um 13:30 Uhr ET teilnehmen.
Live-Webcasts und Wiederholungen sind über die Investor-Relations-Website des Unternehmens unter ir.tourmalinebio.com unter 'Events und Präsentationen' zugänglich.
- None.
- None.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences:
Truist Securities BioPharma Symposium, New York
Panel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses
Thursday, November 7, 2024 at 2:35 pm ET
Guggenheim Securities Healthcare Innovation Conference, Boston
Fireside Chat
Tuesday, November 12, 2024 at 1:30 pm ET
Live webcasts and replays, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.
For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
When is Tourmaline Bio (TRML) presenting at the Truist Securities BioPharma Symposium?
What conferences is Tourmaline Bio (TRML) attending in November 2024?
Where can investors watch Tourmaline Bio's (TRML) conference presentations?
